Parkinson’s disease is a progressive neurological disorder in which parts of the brain become damaged over many years, particularly neural systems involved in movement. It is the most common form of parkinsonism, a broader term describing syndromes involving combinations of movement slowing, rigidity and tremor. The defining pathological feature of Parkinson’s disease is degeneration of dopamine-producing nerve cells in a region of the midbrain called the substantia nigra.
Dopamine is a neurotransmitter that participates in neural circuits controlling and coordinating movement. As dopamine-producing neurons are lost, signalling within motor circuits becomes impaired, contributing to the characteristic movement abnormalities. The disease is progressive, meaning symptoms generally develop and become more significant over time, although the speed and exact pattern of progression vary considerably between individuals.
Parkinson’s disease is not simply a tremor disorder. Its principal motor features are resting tremor, bradykinesia and rigidity. Resting tremor commonly begins in a hand or arm and is more noticeable when the affected limb is relaxed. Bradykinesia means slowness of movement and can manifest as reduced arm swing, small shuffling steps, difficulty initiating movement, slower dressing or reduced speed when performing routine tasks.
Rigidity refers to increased resistance and stiffness in muscles and can contribute to discomfort, reduced range of movement and changes in posture. Balance impairment can develop as the disease progresses and increases the risk of falls. These symptoms result from dysfunction of motor circuits rather than simply weakness of muscles, which is why Parkinson’s disease is fundamentally a disorder of neurological movement control.
Parkinson’s disease also has many non-motor manifestations. Loss of the sense of smell, or anosmia, may occur years before obvious movement symptoms. Constipation, urinary problems, sleep disturbance, excessive sweating, sexual dysfunction, dizziness caused by postural blood-pressure reduction and swallowing difficulties can occur. Neuropathic pain and other unpleasant sensory symptoms may also be experienced. Psychiatric and cognitive symptoms include depression, anxiety, mild cognitive impairment and, in some people, dementia. Sleep disorders can include insomnia and excessive daytime sleepiness. The breadth of these symptoms reflects the fact that Parkinson’s disease affects several neural systems rather than a single movement pathway. Consequently, two people with the same diagnosis may have substantially different combinations of motor, autonomic, sensory, sleep, psychiatric and cognitive symptoms.
Parkinson’s disease should be distinguished from parkinsonism. Parkinsonism describes a clinical syndrome characterised principally by movement slowing, rigidity and often tremor, whereas Parkinson’s disease is a specific neurodegenerative disorder causing one form of that syndrome. Other causes of parkinsonism include certain medicines, cerebrovascular disease and other progressive neurological conditions such as progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration. Drug-induced parkinsonism, for example, can occur with some medicines and may improve after the causative medicine is discontinued under medical supervision. This distinction matters because treatment, prognosis and associated symptoms depend on the underlying disorder. A person exhibiting Parkinson-like movements therefore does not automatically have idiopathic Parkinson’s disease.
Parkinson’s disease usually begins after the age of 50, although younger-onset disease can occur, including onset before 40. The condition affects people of both sexes, with men slightly more likely to develop it according to NHS information. There is no single diagnostic laboratory test that conclusively establishes Parkinson’s disease. Diagnosis is primarily clinical and depends on the history of symptoms, neurological examination and assessment of movement.
Doctors may ask the person to walk, move their limbs or perform other physical tasks to assess characteristic abnormalities. In selected cases, specialised imaging such as dopamine-transporter SPECT may assist in distinguishing Parkinsonian syndromes from some alternative explanations, but it is not a universal definitive test. The gradual nature of early symptoms can make diagnosis challenging, particularly when manifestations are mild or atypical.
The underlying disease process involves progressive loss of dopamine-producing neurons in the substantia nigra. Dopamine normally participates in basal-ganglia circuits that help select, initiate and coordinate movements. As dopaminergic signalling declines, the balance of activity within these circuits changes, producing characteristic motor abnormalities. Symptoms generally become clinically apparent only after substantial loss of dopaminergic neuronal function has occurred, meaning pathological changes may precede obvious clinical manifestations by years.
Parkinson’s disease is therefore different from a transient disturbance of movement caused by fatigue, injury or medication. It is a chronic neurodegenerative process in which cellular degeneration progressively alters brain circuitry. The precise mechanisms producing neuronal death are still under investigation and are thought to involve interactions between genetic susceptibility, cellular processes and environmental exposures.
There is currently no cure that reverses the underlying neurodegeneration, but treatment can reduce symptoms and help preserve function and quality of life. Pharmacological treatment commonly aims to increase or replace effective dopaminergic signalling, while physiotherapy, occupational therapy, speech and language therapy and other supportive approaches address mobility, daily activities, communication and swallowing. Treatment is individualised because symptoms and responses vary. Some people eventually require more complex therapies when conventional medication becomes insufficient or produces problematic fluctuations. Management also involves recognising non-motor symptoms because depression, constipation, sleep problems, blood-pressure changes and cognitive impairment can substantially affect wellbeing and independence. Parkinson’s disease is therefore managed as a multidimensional neurological condition rather than solely as a disorder of tremor and movement.
The historical name Parkinson’s disease derives from James Parkinson, the English physician who described the clinical syndrome in his 1817 essay “An Essay on the Shaking Palsy”. Modern understanding is considerably broader than the original description because research has demonstrated that the disorder involves multiple neurological systems and many non-motor symptoms. Contemporary diagnosis and management therefore consider tremor, bradykinesia, rigidity, gait, posture, autonomic function, sleep, mood, cognition, sensory symptoms and other manifestations. The term “Parkinson’s” should also not be used interchangeably with every condition producing a Parkinson-like appearance. Understanding the distinction between Parkinson’s disease, parkinsonism and atypical or secondary parkinsonian syndromes is essential for accurate communication, diagnosis and treatment planning.
